MBX Biosciences started the phase three Canvu Paratide study and plans a C1 data disclosure for 4291, which showed 7% weight loss at eight weeks; cash runway guidance extends into 2029.
MBX · MBX Biosciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
MBX Biosciences reported $481.6 million in cash, cash equivalents and marketable securities at September 30, 2026, expecting existing resources to fund operations into 2029. Nine-month net loss was $123.0 million, versus $64.9 million in 2025.
MBX Biosciences began enrollment in the pivotal Phase 3 oPTimize trial of once-weekly canvuparatide. Cash and investments were $481.6 million at September 30, 2026, expected to fund operations into 2029; third-quarter net loss was $62.4 million.
MBX Biosciences appointed Peter Radovich as an independent director and set the board at eight directors. His initial compensation includes a non-qualified stock option for 18,200 shares.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MBX
this stock
MBX Biosciences, Inc.
|
$2.64B | +68.4% | — | — | 8.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.35B | +18.6% | +46.2% | 34.6 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.52B | +23.4% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$87.10B | +630.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$65.26B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 29
MBX Biosciences started the phase three Canvu Paratide study and plans a C1 data disclosure for 4291, which showed 7% weight loss at eight weeks; cash runway guidance extends into 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MBX | -1.7% | +1.2% | +66.6% | -4.9% | +68.4% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -0.1% | +4.7% | +68.0% | -2.8% | +59.9% |